ZVRAHIGH SIGNALFINANCIAL10-K

ZVRA achieved a dramatic turnaround from a $105.5M net loss to $83.2M net income, while significantly strengthening its balance sheet with stockholders' equity increasing 290% and current assets growing 159%.

This represents a fundamental transformation in ZVRA's financial profile, moving from substantial losses to profitability while dramatically improving liquidity and capital structure. The company appears to have successfully navigated its commercialization challenges and established a much stronger financial foundation for future operations.

Comparing 2026-03-09 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

ZVRA experienced a remarkable financial turnaround with net income swinging from -$105.5M to +$83.2M, while operating cash flow improved 98% from -$69.7M to -$1.6M, indicating near break-even operational performance. The balance sheet was substantially strengthened with stockholders' equity growing 290% to $154.7M, current assets increasing 159% to $223.0M, and cash nearly doubling to $62.4M, though SG&A expenses rose 41.5% likely reflecting increased commercialization efforts. Overall, the financial picture signals a successful transition from a loss-making development-stage company to a profitable commercial entity with significantly improved capital position and liquidity.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+348.1%
$335K$1.5M

Interest expense surged 348.1% — significant debt increase or rising rates materially impacting earnings.

Stockholders Equity
Balance Sheet
+289.9%
$39.7M$154.7M

Equity base grew 289.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Net Income
P&L
+178.9%
-$105.5M$83.2M

Net income grew 178.9% — bottom-line growth signals improving overall business health.

Current Assets
Balance Sheet
+159.2%
$86.0M$223.0M

Current assets grew 159.2% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
+97.7%
-$69.7M-$1.6M

Operating cash flow surged 97.7% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
+84.7%
$33.8M$62.4M

Cash position surged 84.7% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+59.8%
$178.1M$284.7M

Asset base grew 59.8% — expansion through organic growth, acquisitions, or capital deployment.

SG&A Expense
P&L
+41.5%
$54.9M$77.6M

SG&A up 41.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Accounts Receivable
Balance Sheet
-36.9%
$16.1M$10.2M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Income
P&L
+27.7%
-$87.0M-$62.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-12
ADDED
001-36913 ______________________________________________________________________ Zevra Therapeutics, Inc.
A s of March 6, 2026, the registr ant had 58,711,584 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 55 Item 7A.
The outcomes of the events described in these forward-looking statements are subject to risks, uncertainties and other factors described in Risk Factors and elsewhere in this report.
These risks are discussed more fully in the section titled Risk Factors .
+7 more — sign up free →
REMOVED
A s of March 7 , 2025, the registrant had 54,115,869 shares of common stock outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 82 Item 7A.
The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in Risk Factors and elsewhere in this report.
These risks are discussed more fully in the section titled "Risk Factors".
Material risks that may affect our business, financial condition, results of operations, and trading price of our common stock include the following: If commercialization of our approved products, or any of our product candidates, if approved, are not successful, or we experience significant delays in commercialization, our business will be harmed.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →